Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT06167317 as recruiting, last updated 2026-08-13. Enrolment is 278 planned participants, an estimate. Interventions: GS-0201, Sacituzumab Govitecan. Primary measures include The Number of Participants with Dose Limiting Toxicities (DLTs) During Dose Escalation; The Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs). No results are posted in the registry; this does not exclude separate publications.
Shares Sacituzumab govitecan, TROP2.
Shares Sacituzumab govitecan, TROP2.
Shares Sacituzumab govitecan, TROP2.
Shares Sacituzumab govitecan, TROP2.
Shares Sacituzumab govitecan, TROP2.
Shares Sacituzumab govitecan, TROP2.
Shares Sacituzumab govitecan, TROP2.
Shares Sacituzumab govitecan, TROP2.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/